Clinical trials: Essential Hypertension.
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015 and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fed conditions
- Trial name
- NCT06744439
- Testing
- BR1015, BR1015-2, BR1015-3
- Where
- South Korea
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HT
To investigate the impact of antihypertensive therapy with the selective mineralocorticoid receptor blocker, eplerenone, on small resistance artery remodeling, compared to the effect of equivalent blood pressure control achieved…
- Trial name
- NCT00147563
- Testing
- Eplerenone
- Where
- Canada
- Volunteers
- 34 people
- Sponsor
- Pfizer
Essential Hypertension
Safety and Efficacy of Modulated Ultrasound Renal Denervation for HTN（FIM）
This study is a prospective and exploratory clinical study, enrolling patients with essential hypertension. This study is planned to be conducted in 2 research institutions in China, and a total of 6 subjects are planned to be…
- Trial name
- ModulationHTN1 (NCT06877234)
- Testing
- Ultrasonic Nerve Ablation System
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shenzhen Pulsecare Medical Technology Co., Ltd.
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-1 and BR1015-2 in healthy volunteers under fed conditions
- Trial name
- NCT07421388
- Testing
- BR1015-A, BR1015-1, BR1015-2
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Hyzaar Asia HEAALTH (0954A-950)
The objective of the study is to estimate the percentage of patients who reach blood pressure goal after 8 weeks of treatment with losartan/HCTZ combination.
- Trial name
- NCT00354991
- Testing
- losartan potassium (+) hydrochlorothiazide
- Volunteers
- 437 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension
A Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient
The changes in the trough systolic blood pressure from the baseline were assessed after 8 weeks of double-blind treatment with amlodipine 10 mg or amlodipine 5 mg
- Trial name
- NCT00415623
- Testing
- Amlodipine
- Where
- 14 sites in Japan
- Volunteers
- 305 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015 and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fasting conditions
- Trial name
- NCT06744426
- Testing
- BR1015, BR1015-2, BR1015-3
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
CKD-828(80/2.5mg) Pharmacokinetic Study_2nd
The purpose of this study is to evaluate the pharmacokinetic characteristics of CKD-828(Fixed Dose Combination Tablet; Telmisartan and S-Amlodipine) in healthy volunteer.
- Trial name
- NCT01352689
- Testing
- CKD-828(FDC), Combination Therapy
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension,Essential
A Study to Evaluate the Efficacy and Safety of AD-223
The purpose of this study is to evaluate the efficacy and safety of AD-223
- Trial name
- NCT06052748
- Testing
- AD-223A, AD-223B, AD-223C
- Where
- South Korea
- Volunteers
- 502 people
- Sponsor
- Addpharma Inc.
Mild Hypertension
A Study in People With Mild Hypertension
The primary objective of this study is to test the hypothesis that LY518674, administered for 6 weeks to patients with mild hypertension, reduces Systolic Blood Pressure, compared with placebo.
- Trial name
- NCT00374855
- Testing
- PPAR alpha, Hydrochlorothiazide
- Where
- 10 sites in Sweden
- Volunteers
- 153 people
- Sponsor
- Eli Lilly and Company
Essential Hypertension
Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential Hypertension
The purpose of this study is to evaluate the safety and efficacy of fixed combination of lercanidipine (10 mg or 20 mg) and valsartan (80 mg or 160 mg), lercanidipine and valsartan alone in reducing blood pressure.
- Trial name
- NCT01122251
- Testing
- Lercanidipine + Valsartan, Lercanidipine or Valsartan
- Where
- 2 sites in South Korea
- Volunteers
- 441 people
- Sponsor
- LG Life Sciences
Hypertension
FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry)
To determine whether the combination of nifedipine GITS and valsartan is more effective in reducing central blood pressure than nifedipine GITS or valsartan alone, and to determine whether nifedipine GITS is comparable to…
- Trial name
- NCT01071122
- Testing
- Nifedipine (Adalat, BAYA1040) and Valsartan, Nifedipine (Adalat, BAYA1040), Valsartan
- Where
- 15 sites in South Korea
- Volunteers
- 365 people
- Sponsor
- Bayer
Hypertension
CKD-828 (40/5mg) Pharmacokinetic Study
The purpose of this study is to evaluate the pharmacokinetic characteristics of CKD-828 (Fixed Dose Combination Tablet; Telmisartan and S-Amlodipine) in healthy volunteer.
- Trial name
- NCT01340131
- Testing
- CKD-828, Combination Therapy
- Where
- South Korea
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension
The purpose of this study is to evaluate the effectiveness and safety of azilsartan medoxomil compared to placebo, once daily (QD), in African-American participants with essential hypertension.
- Trial name
- NCT00591253
- Testing
- Azilsartan medoxomil
- Where
- 64 sites in United States, Puerto Rico
- Volunteers
- 413 people
- Sponsor
- Takeda
Essential Hypertension
Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension
To examine antihypertensive effect, pharmacodynamics, and safety of long-term administration of CS-3150 as monotherapy and in combination with calcium channel blocker or renin-angiotensin system inhibitor in patients with…
- Trial name
- NCT02722265
- Testing
- CS-3150
- Where
- Japan
- Volunteers
- 368 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Essential Hypertension
Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients
Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison with Telmisartan/Amlodipine Combination for Essential Hypertension…
- Trial name
- NCT02738632
- Testing
- Telmisartan/Amlodipine+Hydrochlorothiazide, Telmisartan/Amlodipine
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Hypertension
Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals
The aim of the observational study was to supplement the data on efficacy, safety and tolerability of telmisartan under daily conditions in hospitals
- Trial name
- NCT02238262
- Testing
- Telmisartan
- Volunteers
- 2,318 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Primary Hypercholesterolaemia
To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase 3 trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary…
- Trial name
- HODO-2224 (NCT06646354)
- Testing
- Ezetimibe/Rosuvastatin/Candesartan/Amlodipine, Candesartan/Amlodipine, Candesartan/Rosuvastatin/Ezetimibe
- Where
- South Korea
- Volunteers
- 125 people
- Sponsor
- Hyundai Pharm
Essential Hypertension, Type 2 Diabetes Mellitus
Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil (AZM) in Asian adult participants with both essential hypertension and type 2 diabetes.
- Trial name
- NCT02517866
- Testing
- Azilsartan Medoxomil
- Where
- 11 sites in China, Taiwan and 1 more
- Volunteers
- 380 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2, Essential Hypertension
Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea
This study was designed to evaluate the anti-hypertensive efficacy of lacidipine in hypertensives with Type 2 diabetes and effectiveness on endothelial cell function in Korean population.
- Trial name
- NCT00328965
- Testing
- Lacidipine
- Sponsor
- GlaxoSmithKline